Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.51 |
| ▸ | PREP | P48147 | 5/20 | 0.50 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.48 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977446 | 0.97 | PREP (0.53) | PREPNPSR1ACE2ALDH1A1 | |
| SCHEMBL791439 | 0.87 | PREP (0.57) | PREPNPSR1ACE2ALDH1A1 | |
| SCHEMBL13994810 | 0.87 | PREP (0.57) | PREPNPSR1ACE2ALDH1A1 | |
| SCHEMBL30872568 | 0.85 | ABHD6 (0.49) | FKBP1APREPABHD6DAGLATMEM97 | |
| SCHEMBL8303315 | 0.85 | CTSK (0.52) | FKBP1APREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL3354292 | 0.84 | PREP (0.54) | FKBP1APREPTMEM97SIGMAR1NPSR1 | |
| SCHEMBL13567881 | 0.83 | PREP (0.52) | FKBP1APREPNPSR1ACE2ALDH1A1 | |
| SCHEMBL13198885 | 0.83 | NPC1 (0.60) | FKBP1APREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL14646609 | 0.83 | NPC1 (0.60) | FKBP1APREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL10899658 | 0.82 | PREP (0.51) | PREPNPSR1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| CN-1688527-A | Fused benzene derivatives and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | FKBP1A 1634/4885PREP 4275/4885ABHD6 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.